Pre-made Pertuzumab benchmark antibody ( Whole mAb, anti-ERBB2/HER2 therapeutic antibody, Anti-CD340/neu/MLN 19/NEU/NGL/TKR1/VSCN2 Antibody) for drug discovery and mechanism of action (MOA) research
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry
Product Details
Pre-Made Pertuzumab biosimilar, Whole mAb, Anti-ERBB2/HER2 Antibody: Anti-CD340/neu/MLN 19/NEU/NGL/TKR1/VSCN2 therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Pertuzumab (also called 2C4, trade name Perjeta) is a monoclonal antibody used in combination with trastuzumab and docetaxel for the treatment of metastatic HER2-positive breast cancer; it also used in the same combination as a neoadjuvant in early HER2-positive breast cancer.
| Products Name (INN Index) | Pre-Made Pertuzumab biosimilar, Whole mAb, Anti-ERBB2/HER2 Antibody: Anti-CD340/neu/MLN 19/NEU/NGL/TKR1/VSCN2 therapeutic antibody |
|---|---|
| INN Name | Pertuzumab |
| Target | ERBB2 |
| Format | Whole mAb |
| Derivation | Humanized |
| Species Reactivity | Human |
| CH1 Isotype | IgG1 |
| VD LC | Kappa |
| Highest_Clin_Trial (Jan '20) | Approved |
| Est. Status | Active |
| 100% SI Structure | 1l7i:HL/4llu:AB:CD/1s78:FE:DC |
| 99% SI Structure | None |
| 95-98% SI Structure | 4lly:AB:CD/4llw:CD:AB/5vsh:CD:AB:EF:HL |
| Year Proposed | 2003 |
| Year Recommended | 2004 |
| Companies | Chugai Pharmaceutical,Dana-Farber Cancer Institute,FONDAZIONE DEL PIEMONTE PER L'ONCOLOGIA IRCC DI CANDIOLO,Genentech,International Breast Cancer Study Group,Japan Breast Cancer Research Group,Medica |
| Conditions Approved | Breast cancer |
| Conditions Active | Ovarian cancer,Brain metastases,Colorectal cancer |
| Conditions Discontinued | Gastric cancer,Non-small cell lung cancer,Prostate cancer |
| Development Tech | NA |
| Previous Name | NA |
| Gm Offical Target Name | ERBB2 |
| Package |
